Scynexis (SCYX) Return on Capital Employed (2014 - 2026)
Scynexis' (SCYX) quarterly Return on Capital Employed came in at 46.51% in Q1 2026, up 500.0% YoY from 7.75% in Q1 2025, and down 42.86% on a QoQ basis from 32.56% in Q4 2025.
Scynexis (SCYX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Scynexis (SCYX) has 13 years of Return on Capital Employed data on file, last reported at 46.51% in Q1 2026.
- Quarterly Return on Capital Employed rose 500.0% year-over-year to 46.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46.51% (up 500.0% YoY) and the FY2025 annual result came in at 23.26%, up 2019.0% from the prior year.
- Return on Capital Employed declined to 46.51% in Q1 2026, from 32.56% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 76.93% in Q1 2024 to a low of 229.58% in Q1 2023.
- A 5-year average of 44.82% and a median of 59.12% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 15272 bps — and 2024, when it soared 30652 bps.
- Tracing SCYX's Return on Capital Employed over 5 years: stood at 104.03% in 2022, then surged by 157 bps to 59.48% in 2023, then plunged by 188 bps to 52.47% in 2024, then jumped by 38 bps to 32.56% in 2025, then slumped by 43 bps to 46.51% in 2026.
- The last three Return on Capital Employed figures came in at 46.51% (Q1 2026), 32.56% (Q4 2025), and 73.04% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | -32.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.07% |
| Mar 31, 2026 | -46.51% |
| Dec 31, 2025 | -32.56% |
| Sep 30, 2025 | -73.04% |
| Jun 30, 2025 | -68.38% |
| Mar 31, 2025 | -51.51% |
| Dec 31, 2024 | -52.47% |
| Sep 30, 2024 | -67.09% |
| Jun 30, 2024 | -59.12% |
| Mar 31, 2024 | 76.93% |
| Dec 31, 2023 | 59.48% |
| Sep 30, 2023 | 54.30% |
| Jun 30, 2023 | 63.84% |
| Mar 31, 2023 | -229.58% |
| Dec 31, 2022 | -104.03% |
| Sep 30, 2022 | -78.02% |
| Jun 30, 2022 | -77.35% |
| Mar 31, 2022 | -76.87% |
| Dec 31, 2021 | -60.09% |
| Sep 30, 2021 | -52.68% |